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Abstract
The CDK7 inhibitors (CDK7i) ICEC0942 and THZ1, are promising new cancer therapeutics. Resistance to targeted drugs
frequently compromises cancer treatment. We sought to identify mechanisms by which cancer cells may become resistant to
CDK7i. Resistant lines were established through continuous drug selection. ABC-transporter copy number, expression and
activity were examined using real-time PCR, immunoblotting and ﬂow cytometry. Drug responses were measured using
growth assays. ABCB1 was upregulated in ICEC0942-resistant cells and there was cross-resistance to THZ1. THZ1-resistant
cells upregulated ABCG2 but remained sensitive to ICEC0942. Drug resistance in both cell lines was reversible upon
inhibition of ABC-transporters. CDK7i response was altered in adriamycin- and mitoxantrone-resistant cell lines
demonstrating ABC-transporter upregulation. ABCB1 expression correlated with ICEC0942 and THZ1 response, and
ABCG2 expression with THZ2 response, in a panel of cancer cell lines. We have identiﬁed ABCB1 upregulation as a
common mechanism of resistance to ICEC0942 and THZ1, and conﬁrmed that ABCG2 upregulation is a mechanism of
resistance to THZ1. The identiﬁcation of potential mechanisms of CDK7i resistance and differences in susceptibility of
ICEC0942 and THZ1 to ABC-transporters, may help guide their future clinical use.
Introduction
Cyclin dependent kinase (CDK7), along with cyclin H and
the accessory protein MAT1, forms the CDK-activating
kinase (CAK), which functions to activate CDKs by T-loop
phosphorylation [1]. CAK activity directs cell cycle pro-
gression via phosphorylation of CDK1, CDK2, CDK4 and
CDK6 [2]. CAK is also a component of the general tran-
scription factor TFIIH, which is recruited to transcription
start sites, along with the other components of the basal
transcriptional machinery, where it phosphorylates RNA
polymerase II (Pol II) at serine-5 and serine-7 in its C-
terminal domain (CTD) heptapeptide repeats [3]. This Pol II
CTD phosphorylation is required for transcription initiation,
and therefore, together with its role in regulating the cell
cycle, CDK7 is also critical for regulating transcription.
CDK9, a component of positive transcription elongation
factor (P-TEFb), is likewise activated by CDK7, which in
turn results in phosphorylation of the Pol II CTD at serine-2,
enabling transcription elongation [4]. In addition, CDK7
also plays a role in activating multiple transcription factors,
including the retinoic acid [5], oestrogen [6] and androgen
receptors [7], and p53 [8].
Cell cycle deregulation is a common feature of cancer
and a number of cell cycle CDK inhibitors have been
approved as cancer therapeutics, most prominently CDK4/6
inhibitors, exempliﬁed by palbociclib, for the treatment of
advanced oestrogen receptor positive (ER+) breast cancer
[9]. By contrast, it was initially thought that the essential
nature of transcription would make this process a poor
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cancer therapeutic target, where transcriptional inhibitors
would result in general toxicity and a limited therapeutic
window. However, it has now been shown that many
tumour types are more heavily dependent than normal tis-
sues on the activity of key transcriptional drivers, for
example RUNX1 in acute lymphoblastic leukaemia (ALL)
[10] and N-myc in neuroblastoma [10], and also on super-
enhancer driven transcription [10–13]. Recently, these
ﬁndings have become embodied in a wider framework
known as “Transcription addiction in cancer” [14], a con-
cept that supports CDK7 as a potentially valuable cancer
drug target, as it plays key roles in both the regulation of
transcription and the cell cycle. We reported the ﬁrst
selective CDK7 inhibitor, BS-181, as an ATP-competitive
CDK7 inhibitor [15], which served as a lead compound for
development of the oral clinical candidate ICEC0942 [16],
which is currently undergoing Phase I trial for advanced
solid malignancies, under the name CT7001. A second,
covalent CDK7 inhibitor, THZ1 [10], has been indepen-
dently developed and a THZ1-derived compound SY-1365
[17] is also undergoing Phase I trial for advanced solid
malignancies.
The emergence of resistance to cancer treatment remains
a major problem in cancer therapy. Cancer cells can adapt
and become resistant to drugs in a multitude of ways,
including, but not limited to, mutations that disrupt drug-
target engagement, activating mutations in drug targets and
downstream pathways, changes in gene expression levels of
targets, altered drug metabolism and alterations in cell death
pathways [18]. In addition, the upregulation of ATP-
dependent efﬂux pumps with broad substrate speciﬁcity can
result in multi-drug resistance. The most well-described
examples of these are: ATP-binding cassette subfamily B
member 1 (ABCB1), also known as multidrug resistance
protein 1 or P-glycoprotein; ATP-binding cassette sub-
family C member 1 (ABCC1), or multidrug resistance-
associated protein 1, and ATP-binding cassette subfamily G
member 2 (ABCG2), also known as breast cancer resistance
protein [19]. When these ABC-transporter pumps are
upregulated, drugs that are substrates are actively efﬂuxed
from cancer cells, resulting in decreased intracellular drug
accumulation.
Whilst CDK7 inhibitors (CDK7i) represent a promising
therapeutic approach, development of resistance in the
clinic is possible, therefore identifying potential resistance
mechanisms preemptively is of great importance. We have
developed models of acquired resistance to both
ICEC0942 and THZ1 in the breast cancer cell line MCF7,
identifying upregulation of ABC-transporters as media-
tors of resistance. These ﬁndings may be informative for
future patient selection strategies and combination treat-
ment regimes.
Results
Creation of breast cancer cell lines with resistance to
THZ1 and ICEC0942
To investigate mechanisms of acquired resistance to the
CDK7i ICEC0942 and THZ1, we generated MCF7-derived
drug resistant cell lines through prolonged culturing in the
presence of ICEC0942 or THZ1. THZ1 resistance was
achieved by initially exposing the cells to 50 nM THZ1,
approximately the concentration required for 50% growth
inhibition. This was increased gradually up to a con-
centration of 250 nM, with passaging once a week, until the
cells became stably THZ1-resistant after 3 months. A dif-
ferent strategy was used to achieve ICEC0942 resistance, as
even cells exposed to drug concentrations well below IC50
became growth-arrested after 1–2 weeks, so could not be
continually passaged. Cells treated with 800 nM ICEC0942
remained growth arrested until resistance developed after
4 months, eventually giving rise to the ICEC0942-resistant
line (MCF7-942R).
Compared with MCF7, MCF7-942R showed a 29-fold
resistance to ICEC0942 (P= 0.0006; Fig. 1a, e), and the
THZ1-resistant cell line (MCF7-THZ1R) showed a 13-fold
resistance to THZ1 (P= 0.001; Fig. 1c, e). MCF7-942R also
exhibited signiﬁcant cross-resistance to THZ1, with a
sevenfold increase in GI50 (P < 0.0001; Fig. 1b, e). Inter-
estingly however, MCF7-THZ1R remained sensitive to
ICEC0942 (Fig. 1d, e). We examined Pol II CTD phos-
phorylation by western blotting after treatment with 1 µM
ICEC0942 or 0.4 µM THZ1, concentrations at which
maximal differences in growth inhibition between resistant
and parental cell lines are observed (Fig. 1a–d). Quantiﬁ-
cation of three independent experiments showed that
ICEC0942 and THZ1 treatment signiﬁcantly reduced
phosphorylation of serine-2, serine-5 and serine-7 in MCF7,
whereas in MCF7-942R, Pol II CTD phosphorylation was
unaffected. However, in MCF7-THZ1R, whilst Pol II CTD
phosphorylation was unaltered after THZ1 treatment,
phosphorylation was reduced after ICEC0942 treatment
(Fig. 1f and Supplementary Fig. S1).
THZ1 inhibits CDK7 by covalently targeting a cysteine
residue (C312), which lies outside the ATP-binding domain
[10], whereas ICEC0942 is an ATP-competitive CDK7i
[16]. It has been shown that mutation of C312 to serine
(C312S), is sufﬁcient to prevent THZ1 from covalently
binding to CDK7 and from inhibiting CDK7 activity [10],
therefore it was possible that a mutation of C312 could be
responsible for the THZ1-resistance and continued sensi-
tivity to ICEC0942 in MCF7-THZ1R. However, DNA
sequencing conﬁrmed no sequence change between MCF7
and MCF7-THZ1R at C312 (Supplementary Fig. S2).
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Fig. 1 Cross-resistance of ICEC0942- and THZ1- resistant breast
cancer cell lines. MCF7, MCF7-942R and MCF7-THZ1R were treated
with increasing concentrations of ICEC0942 (a, d) or THZ1 (b, c) for
48 h. Mean growth is shown relative to that for vehicle (DMSO)-
treated cells. Dose-response curves shown are from single, repre-
sentative experiments. Average GI50 values of the dose response
curves (±SEM, n= 3 independent experiments) of ICEC0942 and
THZ1, and fold-resistance of MCF7-942R and MCF7-THZ1R, relative
to MCF7, are summarised in e. P values indicate the statistical sig-
niﬁcance of the fold resistance. Protein lysates from MCF7, MCF7-
942R and MCF7-THZ1R, treated with THZ1 or ICEC0942 at indicated
concentrations for 24 h, were immunoblotted for Pol II and for phos-
phorylation of serine-2, serine-5 and serine-7 in the Pol II C-terminal
domain (representative of three independent experiments; see Sup-
plementary Fig. S2 for quantiﬁcation) (f)
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Subsequently, the full coding sequence of CDK7 was
sequenced in MCF7, MCF7-942R and MCF7-THZ1R and
no mutations in CDK7 were identiﬁed (data not shown).
THZ1 and ICEC0942 resistance leads to increased
expression of ABC-transporters
Since upregulation of ABC-transporters is a common
mechanism of cancer drug resistance, we used qRT-PCR to
examine the mRNA levels of the most frequently observed
transporters, ABCB1, ABCC1 and ABCG2, in our CDK7
inhibitor-resistant cell lines. ABCG2 and ABCB1 expres-
sion was absent/very low in MCF7 cells, but there was
appreciable expression of ABCC1 (Fig. 2a, b). While
ABCB1 and ABCC1 expression was unchanged in MCF7-
THZR cells, ABCG2 expression was increased 140-fold,
relative to MCF7 cells (Fig. 2a). ABCG2 expression was
also around sevenfold higher in In MCF7-942R, although its
expression remained low. Importantly, there was consider-
able increase in ABCB1 expression in MCF7-942R
(Fig. 2b). Western blotting conﬁrmed the upregulation of
ABCB1 in MCF7-942R and of ABCG2 in MCF7-THZ1R
(Fig. 2c), while the low-level increase in ABCG2 expres-
sion cells was not detectable in MCF7-942R cells.
We next used quantitative gene copy number measure-
ment to determine if the upregulation in ABCB1 and
Fig. 2 Increased expression of ABC-transporters in ICEC0942- and
THZ1- resistant cell lines. mRNA levels of ABCB1, ABCG2 and
ABCC1 were compared in MCF7, MCF7-THZ1R (a) and MCF7-942R
(b) by qRT-PCR (error bars= SEM; n= 3). ABCB1 and ABCG2
protein expression were compared in MCF7, MCF7-942R and MCF7-
THZ1R by immunoblotting (c). ABCB1 and ABCG2 copy number
were compared across the cell lines, and in control genomic DNA, by
TaqMan-based copy number analysis (d). Predicted copy number,
relative to the RNase P gene, was calculated using CopyCaller®
Software (error bars= SD; n= 4)
G. P. Sava et al.
ABCG2 expression was reﬂected in ampliﬁcation of the
ABCB1 and ABCG2 genes in the resistant cell lines. The
gene copy number analysis suggests that there is modest
gene ampliﬁcation in the resistant cell lines, with an esti-
mated six copies of ABCB1 in MCF7-942R and three copies
of ABCG2 in MCF7-THZ1R, relative to two copies of both
genes in MCF7 (Fig. 2d). In MCF7-THZ1R there was also a
predicted ampliﬁcation of ABCB1, however this is not
reﬂected in the mRNA or protein (Fig. 2a, c and d). Simi-
larly, an increase in ABCG2 mRNA expression seen in
MCF7-942R is not reﬂected at the protein level nor at the
level of gene copy number increase.
ABC-transporter mediated efﬂux is increased in
THZ1- and ICEC0942-resistant cell lines
To assess whether upregulation of ABC-transporters in
MCF7-942R and MCF7-THZ1R corresponds with their
increased efﬂux activity, we performed ﬂow cytometry with
ﬂuorescent ABC-transporter substrates, assessing intracel-
lular ﬂuorescence as a reﬂection of pump activity. After
30 min of incubation with the detection reagents, both
resistant cell lines exhibited signiﬁcantly diminished
ﬂuorescence in comparison with MCF7, revealing an
increase in ABC-transporter activity (Fig. 3a–d).
CDK7 inhibitor resistance can be reversed by ABC-
efﬂux pump inhibitors
To explore whether the increase in ABC-transporter activity
in the CDK7 inhibitor-resistant cell lines is responsible for
their drug resistance, we utilised speciﬁc inhibitors of
ABCB1 and ABCG2. ICEC0942-resistant cells were treated
with the ABCB1-speciﬁc inhibitors verapamil [20] and tar-
iquidar [21], alongside increasing concentrations of
ICEC042 or THZ1. Both ABCB1 inhibitors increased the
sensitivity of MCF7-942R cells to ICEC0942 and THZ1 in a
dose dependent manner (Fig. 4a–d). THZ1-resistant cells
were treated with the ABCG2-speciﬁc inhibitors novobiocin
[22] and KO-143 [23], in combination with increasing
concentrations of THZ1. Likewise, both ABCG2 inhibitors
dose-dependently reduced the GI50 of THZ1 in MCF7-
THZ1R (Fig. 4e, f), albeit the increase in sensitivity to THZ1
was more pronounced for KO-143, than for novobiocin,
which is unsurprising considering KO-143 has previously
been shown to be a more potent modulator of ABCG2 [24].
Fig. 3 ABC-transporter mediated efﬂux is altered in ICEC0942-
resistant cells. MCF7 and MCF7-942R were incubated with
EFFLUXX-ID dye (a), and MCF7 and MCF7-THZ1R with Hoechst
33342 (c), and the accumulation of intracellular ﬂuorescence was
measured by ﬂow cytometry every 5 min for 30 min (error bars=
SEM, n= 3). The mean ﬂuorescence intensity at time 0 and 30 min is
shown for MCF7 vs. MCF7-942R (b) and MCF7 vs. MCF7-THZ1R (d)
(error bars= SEM, n= 3). Asterisks represent statistically signiﬁcant
differences (unpaired t-test, *P < 0.05, ****P < 0.0001)
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To further conﬁrm the role of ABC-transporters in CDK7i
resistance, we carried out siRNA knockdown experiments.
The siRNA-mediated reduction of ABCB1 in MCF7-942R
and of ABCG2 in MCF7-THZ1R was conﬁrmed by qRT-
PCR and western blot (Supplementary Fig. S3A–D). In
MCF7-942R, knockdown of ABCB1 resensitised cells to
both ICEC0942 and THZ1 (Supplementary Fig. S3F, G).
Similarly, in MCF7-THZ1R, knockdown of ABCG2 resen-
sitised cells to THZ1 (Supplementary Fig. S3H).
To conﬁrm if ABCB1 upregulation is common, we cultured
an additional independent MCF7 cell stock in ICEC0942, to
generate resistance. ABCB1 was similarly also upregulated in
resistance to ICEC0942 (Supplementary Fig. S4A). ICR-
MCF7-942R had reduced sensitivity to both ICEC0942 and
THZ1, in comparison with its parental cell line, ICR-MCF7
(Supplementary Fig. S4B–E). Like MCF7-942R, treatment of
ICR-MCF7-942R with verapamil or tariquidar, alongside
increasing concentrations of ICEC042 or THZ1, could resen-
sitise the cells to the CDK7i (Supplementary Fig. S4B–E).
To ascertain whether ABC-transporter upregulation
alone, is sufﬁcient for resistance to CDK7i, we utilised
HEK293 cells stably overexpressing either ABCB1
(HEK293ABCB1), ABCG2 (HEK293ABCG2) or empty vector
(HEK293) (Supplementary Fig. S5A). Overexpression of
ABCB1 caused resistance to both THZ1 and ICEC0942.
However, whilst overexpression of ABCG2 resulted in
resistance to THZ1, HEK293ABCG2 remained sensitive to
ICEC0942 (Supplementary Fig. S5B, C).
Fig. 4 ICEC0942 and THZ1 resistance can be reversed by ABC-
transport inhibitors. MCF7, and MCF7-942R were treated with
increasing concentrations of ICEC0942 or THZ1 for 48 h with addi-
tion of the ABCB1 inhibitors, verapamil or tariquidar (at indicated
concentrations), or with vehicle (DMSO) (a–d). MCF7, and MCF7-
THZ1R were treated with increasing concentrations of THZ1 for 48 h
with addition of the ABCG2 inhibitors, novobiocin (e) or KO-143 (f)
(at indicated concentrations), or with vehicle (DMSO). The sum-of-
squares F test was used to assess whether the addition of ABCB1/
ABCG2 inhibitors signiﬁcantly affected the GI50 of ICEC0942 and/or
THZ1, in MCF7-942R and MCF7-THZ1R. The corresponding F
(degrees of freedom in brackets) and P values are presented (a–f).
Dose-response curves shown are from single experiments (error
bars= SEM, n= 6). For clarity, the vehicle control growth curves for
MCF7 and MCF7-THZ1R have been presented in both e, f
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Docking studies were performed to investigate the pos-
sible interactions of ICEC0942 and THZ1 with the drug-
binding pockets of ABCB1 and ABCG2. Whilst both
compounds are likely to interact with ABCB1 and ABCG2,
THZ1 appears to have a stronger overall afﬁnity for both
transporters (Supplementary Fig. S6).
ABCB1 and ABCG2 are correlated with CDK7
inhibitor response in a cancer cell line panel
To establish wider evidence for a relationship between
ABCB1 expression level and ICEC0942 response, we
examined the correlation between mRNA levels of ABCB1
and ICEC0942 GI50 in a panel of 854 cancer cell lines
representing a variety of cancer types [25]. A modest but
signiﬁcant, positive correlation between ABCB1 expression
and ICEC0942 GI50 was observed (P < 0.0001; Fig. 5a). In
contrast, we saw no correlation between ICEC0942 GI50
and ABCG2 expression levels (P= 0.79; Fig. 5b).
Although screening data was not available for THZ1,
THZ2, a THZ1-derived analogue with similar
CDK7 selectivity [26], has been screened using this cancer
cell line panel. An examination of the THZ2 cell line sen-
sitivity data revealed moderate, but signiﬁcant positive
correlations between expression levels of both ABCB1
(P= 0.0001) and ABCG2 (P < 0.0001) and THZ2 response
(Fig. 5c, d).
Chemotherapy-resistant cells are cross-resistant to
CDK7 inhibitors
As upregulation of ABC-transporters represents a mechan-
ism of resistance common to a wide range of cancer drugs,
we wondered whether cell lines with pre-established resis-
tance to chemotherapeutics would also be cross-resistant to
CDK7i. Here we utilised an adriamycin-resistant cell line
from the NCI-60 panel, derived from the ovarian cancer line
OVCAR8 (NCI-ADRR) [27] and a mitoxantrone-resistant
MCF7-derived cell line (MCF7-MXR) [28, 29]. qRT-PCR
conﬁrmed that ABCB1 is highly expressed in NCI-ADRR
(Fig. 6a) and ﬂow cytometry with a ﬂuorescent
ABCB1 substrate (as described above) veriﬁed efﬂux pump
activity (Fig. 6b). NCI-ADRR is completely non-responsive
to both THZ1 and ICEC0942, even at the highest doses
tested (20 µM) (Fig. 6e), whereas OVCAR8 cells are sen-
sitive to ICEC0942 and THZ1, with a GI50 of 1.5 µM ± 0.09
and 0.05 µM ± 0.02, respectively (Fig. 6e).
MCF7-MXR was conﬁrmed to have high expression and
pump activity of ABCG2, by qRT-PCR (Fig. 6c) and ﬂow
cytometry with ﬂuorescent detection reagents (Fig. 6d). This
Fig. 5 Expression of ABC-transporters is correlated with CDK7
inhibitor response in a cancer cell line panel. A panel of 854 cancer
cell lines was screened with ICEC0942 and THZ2 and the GI50 values
for each cell line plotted against their mRNA expression levels of
ABCB1 (a, c) and ABCG2 (b, d). R= Pearson correlation coefﬁcient
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cell line displayed resistance to THZ1, with the highest dose
(20 µM) achieving only around a 50% reduction in cell growth
(Fig. 6f). However, ICEC0942 induced growth inhibition and
cell death in MCF7-MXR at doses above 625 nM (Fig. 6f).
Discussion
Our ﬁndings have identiﬁed upregulation of ABC-
transporters as a potential mechanism of acquired
resistance to CDK7i that are in clinical evaluation. Speciﬁ-
cally, upregulation of ABCB1 can mediate resistance to both
the ATP-competitive inhibitor ICEC0942, and the covalent
inhibitor THZ1, whereas ABCG2 upregulation results in
THZ1-resistance whilst ICEC0942-sensitivity is maintained.
MCF7 cells with acquired resistance to ICEC0942 were
developed, which were cross-resistant to THZ1, showed
ampliﬁcation of the ABCB1 gene and correspondingly,
increased ABCB1 efﬂux activity. A competitive inhibitor of
ABCB1, verapamil [20], and a non-competitive inhibitor,
Fig. 6 Chemotherapy-resistant cell lines are cross-resistant to CDK7
inhibitors. mRNA levels of ABCB1 (a) and ABCG2 (c) were exam-
ined in OVCAR8, NCI-ADRR, MCF7 and MCF7-MXR by qRT-PCR
(error bars= SEM, n= 3). OVCAR8 and NCI-ADRR were incubated
with EFFLUXX-ID dye and MCF7 and MCF7-MXR with Hoechst
33342, and the accumulation of intracellular ﬂuorescence was mea-
sured by ﬂow cytometry every 5 min for 30 min. The mean ﬂuores-
cence intensity at time 0 and 30 min is shown for OVCAR8 vs. NCI-
ADRR (b) and MCF7 vs. MCF7-MXR (d) (error bars= SEM, n= 3).
NCI-ADRR (e) and MCF7-MXR (f) were treated with increasing
concentrations of THZ1 or ICEC0942 for 48 h. Dose-response curves
shown are from single experiments (error bars= SEM, n= 6). Mean
growth is shown relative to that for vehicle (DMSO)-treated cells.
Asterisks represent statistically signiﬁcant differences (unpaired t-test,
**P < 0.01, ****P < 0.0001)
G. P. Sava et al.
tariquidar [30], were able to resensitise the cells to both
CDK7i. This provides evidence for the biological relevance
of ABCB1 activity in the drug resistance of this cell line. In
further support of this, siRNA knockdown of ABCB1 was
also able to reverse the resistance to CDK7i, and ABCB1
overexpression was able to induce resistance to CDK7i.
Prolonged treatment of MCF7 cells with THZ1 resulted in a
THZ1-resistant cell line with gene ampliﬁcation of ABCG2
and a corresponding upregulation of ABCG2. Importantly,
despite an over thirteen-fold resistance to THZ1, these cells
remained sensitive to ICEC0942. Again, sensitivity to
THZ1 in this cell line was restored with inhibitors of
ABCG2, and also with siRNA knockdown of ABCG2,
whereas ABCG2 overexpression could generate resistance
to THZ1. This provides support for a mechanistic role of
ABCG2 in mediating THZ1-resistance.
In a drug screen on a large cancer cell line panel repre-
senting multiple tumour types [25], a signiﬁcant correlation
between the expression of ABCB1 and response to
ICEC0942 was observed across the panel. No screening data
were available for THZ1 in this cell line panel, hence we
made use of cell line response data for THZ2, an analog of
THZ1, which is also selective for CDK7 [26]. ABCB1
expression also correlated signiﬁcantly with THZ2 response,
as did the expression of ABCG2, whereas no correlation
between ABCG2 expression and ICEC0942 sensitivity was
detected. Whilst providing support for the role of ABC-
transporters in mediating CDK7 inhibitor response, this
analysis was based on intrinsic gene expression, whereas the
majority of this study pertains to ABC-transporter upregu-
lation in the acquired resistance setting. In addition, a cell
line with previously acquired adriamycin resistance and high
ABCB1 expression was completely resistant to both CDK7i,
whereas a mitoxantrone-resistant cell line with high ABCG2
expression, although non-responsive to THZ1, retained
some ICEC0942-sensitivity. Taken together these results
suggest that ICEC0942 and THZ1 are both substrates for
ABCB1 transport, and ABCB1 upregulation can mediate
resistance to both drugs. On the other hand, while THZ1
represents a substrate for ABCG2 transport, ICEC0942 is
less readily efﬂuxed by ABCG2, and ABCG2 upregulation
can mediate resistance to THZ1. Docking studies suggest
that ICEC0942 and THZ1 can both interact with ABCB1
and ABCG2, THZ1 with a stronger afﬁnity than ICEC0942.
These studies, however, did not provide insight into struc-
tural differences that could explain the difference in afﬁnity
of ABCG2 for THZ1 over ICEC0942. Hydrophobic regions
have been identiﬁed as a feature common to all
ABCG2 substrates [31], so it is perhaps of note that THZ1
has a higher cLogP value than ICEC0942 (6.33 and 2.85,
respectively) [32], perhaps offering some explanation for the
differing potential of the compounds for ABCG2-mediated
transport. Nevertheless, the differential sensitivity to
ABCG2 may allow broader use of ICEC0942 than THZ1
and/or aid sequencing of the two drugs.
Despite great advances in the development of targeted
anticancer agents, drug resistance remains a major problem
that ultimately limits the effectiveness of almost all known
cancer therapeutics [33]. The recently developed CDK7i,
ICEC0942 and THZ1, have shown great promise for the
treatment of multiple tumour types, including breast cancer.
CDK7 inhibition inhibits the growth of ESR1-mutant breast
cancer [34, 35] and can overcome chemotherapy resistance
in breast cancer [36]. Combinations of CDK7i with other
cancer therapeutics have also been explored, for example,
BRD4 and CDK7i have been shown to work synergistically
in neuroblastoma [37] and a combination of PARP and
CDK7i show synergism for the treatment of Ewing Sar-
coma [38]. Both ICEC0942 and SY-1365, a drug related to
THZ1, are currently undergoing phase I clinical trials for
advanced malignancies; however, it is likely that even if
they are successfully approved as cancer therapies, drug
resistance will be an issue, therefore identifying potential
resistance mechanisms is crucial if this is to be overcome.
Gao et al., previously identiﬁed ABCB1 and ABCG2
upregulation as mechanisms of resistance to THZ1 in neu-
roblastoma and lung cancer cells [39]. Our study conﬁrms
these mechanisms and extends these ﬁndings to breast
cancer. This is the ﬁrst study designed to investigate
mechanisms of resistance to ICEC0942, although both
ABCB1 and ABCG2 have been implicated in resistance to
the pan-CDK inhibitor BS-194, a chemically-related pre-
cursor to ICEC0942 [40]. Our present study suggests that
the structural differences between BS-194 and ICEC0942
have resulted in a reduced afﬁnity of ABCG2 for ICEC0942
compared with BS-194.
Despite the multiple lines of evidence that we present,
demonstrating the role of ABC-transporters in the CDK7
inhibitor-resistance of our cell line models, it is conceivable
that other unidentiﬁed mechanisms of resistance may also be
involved, for example, gene expression changes or mutations
in genes other than CDK7. However, the ability of ABC-
transport inhibition by small molecules and siRNA knock-
down to reverse their drug-resistant phenotypes, strongly
suggests that even if other mechanisms pertaining to CDK7
inhibitor resistance exist in these cells, overactivity of ABC-
transporters provides the predominant mode of resistance.
The ability of cancer cells to acquire resistance to multiple
structurally and mechanistically unrelated drugs severely
limits treatment success in patients [19]. The involvement of
ABC-transporters in drug resistance was initially identiﬁed in
cell lines [41–43], but they have since been implicated in
some clinical settings. Overexpression of ABCB1 has been
shown to be associated with drug resistance in a number of
different tumour types [44], including ceritinib resistance in
non-small cell lung cancer [45], and with poor clinical
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outcomes, such as response to chemotherapy in breast cancer
[46]. In addition, gene rearrangements that fuse the ABCB1
gene with an aberrant active promoter that drives its
expression, have been observed in ovarian cancer [47, 48],
lymphoma [49] and breast cancer [48]. Correlations between
ABCG2 expression and decreased survival [50, 51] and
response to therapy have been identiﬁed, including dasatinib
response in chronic myeloid leukaemia [52].
Despite large efforts, clinical trials of ABC-transport
inhibitors in combination with antineoplastic drugs have
mostly been unsuccessful, due to issues with toxicity,
potency and trial design [19]. However, should future
developments be made in this area, our ﬁndings implicate
CDK7i as potential candidates for combination treatments
with such ABC-transport inhibitors. Our results suggest that
CDK7i may be of most beneﬁt if used before patients have
received multiple lines of chemotherapy, as tumours with
acquired resistance to other therapeutics may have upregu-
lated ABC-transporters, and so may also be cross-resistant to
CDK7i. In this context, tumours with highly upregulated
ABCB1 expression may be unlikely to respond to either
THZ1 or ICEC0942, whereas tumours with high ABCG2
expression may derive beneﬁt from ICEC0942 treatment.
We acknowledge that this study relies heavily on a single
breast cancer cell line model, MCF7. An extension of this work
to other tumour types and in vivo studies would be required to
further investigate the generality of ABC-transporters in CDK7
inhibitor resistance. It is likely that in the clinical setting,
alternative mechanisms of resistance that have not yet been
identiﬁed will be important, for example genomic changes that
activate pathways compensatory for CDK7 inhibition, may
play a role. Further studies will be required to identify these
and grasp a full understanding of the molecular mechanisms
that can give rise to CDK7 inhibitor resistance.
In conclusion, we have identiﬁed upregulation of ABC-
transporters as a mechanism of resistance to two indepen-
dent, selective CDK7i. Upregulation of ABCB1 results in
resistance to both ICEC0942 and THZ1, whereas ABCG2
upregulation can also mediate THZ1 resistance. These
ﬁndings have potential implications for patient selection,
combination treatment strategies and for CDK7 inhibitor
selection, suggesting, for example that it may be beneﬁcial
for CDK7i to be used prior to chemotherapies associated
with ABC-transporter upregulation.
Materials and methods
Cell lines
MCF7 cells were obtained from the ATCC (www.lgcstanda
rds-atcc.org) as frozen stocks. The NCI Adriamycin-resistant
cell line (NCI-ADRR) was provided by Dr. Ernesto Yagüe,
and OVCAR8 by Dr. Paula Cunnea, both from Imperial
College London (London, UK). The MCF7 mitoxantrone-
resistant cell line (MCF7-MXR) was provided by Dr. E
Schneider from the University of Maryland (Baltimore, MD,
USA). HEK293 cells, stably transfected with either empty
pcDNA 3.1 vector (HEK293), pcDNA3.1 containing
ABCB1 (HEK293ABCB1) or ABCG2 (HEK293ABCG2) have
been described [53]. All cell lines were maintained in
DMEM supplemented with 10% FCS, apart from OVCAR8,
which was maintained in RPMI supplemented with 10%
FCS, HEK293 lines, which were maintained in MEM sup-
plemented with 10% FCS and 2 mg/ml geneticin, and ICR-
MCF7/ICR-MCF7-942R, which were maintained in phenol-
red free RPMI, supplemented with 10% FCS and 1 nM
estradiol. Cell lines were cultured up to a maximum of 20
passages beyond initial thawing. Cell cultures were routinely
tested for Mycoplasma infection by assay of culture super-
natants, and found to be negative, using the MycoAlert
Mycoplasma Detection Kit (Lonza, UK).
Establishment of drug resistant cell lines
The MCF7 ICEC0942-resistant cell line (MCF7-942R) was
established by growing MCF7 cells in the continued pre-
sence of ICEC0942 at 800 nM for 4 months, splitting when
cells neared conﬂuence. The MCF7 THZ1-resistant cell line
(MCF7-THZ1R) was established by initially growing MCF7
with THZ1 at 50 nM. Cells were split when they neared
conﬂuence and the THZ1 concentration then raised by 25 nM
increments, up to a maximum of 250 nM, over a 3-month
period. The independent MCF7 ICEC0942-resistant cell line
(ICR-MCF7-942R) was established by growing MCF7 cells
in the continued presence of ICEC0942 at 400 nM for
3 months, splitting when cells neared conﬂuence. After drug
resistance was established, the cell lines were maintained in
culture with 800 nM ICEC0942 (MCF7-942R), 400 nM
ICEC0942 (ICR-MCF7-942R), or 250 nM THZ1 (MCF7-
THZ1R), with medium and drug changes every 3–4 days.
Chemicals
ICEC0942 synthesis has been described [54] and was pro-
vided by Carrick Therapeutics. THZ1 (A8882) was pur-
chased from ApexBio Technology (Boston, MA, USA).
Verapamil (CAY14288), Tariquidar (CAY24180) and KO-
143 (CAY15215) were purchased from Cambridge
Bioscience (Cambridge, UK). Novobiocin (74675) was
purchased from Sigma-Aldrich (Dorset, UK).
Drug sensitivity assays
The sulphorhodamine B (SRB) assay was used to assess
drug sensitivity, as previously described [55]. Drug
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concentrations that inhibited 50% of cell growth (GI50)
were calculated from log dose-response curves in
GraphPad prism v7.0. All dose-response curves are pre-
sented with error bars for standard errors of the mean
(SEM) of six technical replicates. A minimum of three
independent experiments were conducted and the average
fold resistance of the drug resistant cell lines, MCF7-
942R and MCF7-THZ1R, relative to the parental cell line,
MCF7, was determined thus; fold resistance = GI50
resistant cell line/GI50 parental cell line [56]. For ABCB1
and ABCG2 inhibitor studies, the same procedure was
followed, except inhibitors were simultaneously added to
cells with THZ1 or ICEC0942. SRB assays with MCF7
were used to identify non-toxic ABCB1/ABCG2 inhi-
bitor concentrations at 48 h, for use in studies (data not
shown).
Immunoblotting
Whole cell lysates were prepared in RIPA buffer (Sigma-
Aldrich), supplemented with protease and phosphatase inhibi-
tors (Roche, UK), and immunoblotting was carried out as
previously described [16]. Antibodies used were; Pol II
(ab26721), Pol II-phosphoserine-2 (ab5095), Pol II-
phosphoserine-5 (ab5131), Pol II-phosphoserine-7 (ab126537)
and β actin (ab6276), purchased from Abcam (Cambridge,
UK), and ABCB1 (D3H1Q) and ABCG2 (4477), purchased
from Cell Signaling Technology (Danvers, MA, USA). Band
density was quantiﬁed using ImageJ software.
Flow cytometry
The EFLUXX-ID Green Multidrug Resistance Assay Kit
(Enzo Life Sciences, Exeter, UK) was used to assess the
pump efﬂux activity of ABCB1 in MCF7, MCF7-942R and
NCI-ADRR. Cells were trypsinised and resuspended in
phenol red-free DMEM at a concentration of 1 × 106 cells
per ml. Twenty microliters of the EFFLUXX-ID Green
Detection Reagent (in DMSO) was diluted in 1 ml DMEM
(phenol red-free). Cells (2 × 106) were incubated with 50 µl
of the diluted EFFLUXX-ID Green Detection Reagent and
the ﬂuorescence intensity of each sample was measured for
10,000 events every 5 min for 30 min, on a BD LSR II Flow
Cytometer (BD Biosciences, San Jose, CA, USA). The
same procedure was used to assess the pump efﬂux activity
of ABCG2 in, MCF7, MCF7-THZ1R and MCF7-MXR,
except Hoechst 33342 [57] was used instead of EFFLUXX-
ID, at a ﬁnal concentration of 5 µg/ml. This was repeated for
three replicates. Prior to analysis unstained cells were
used for gating. To analyse, the mean ﬂuorescence intensity
of each sample was plotted against time, with error
bars for SEM.
siRNA knockdown
Knockdown of ABCG2 in MCF7-THZ1R cells was carried
out by reverse transfection, using Lipofectamine RNAi-
MAX transfection reagent (Thermo Scientiﬁc), with
ABCG2-speciﬁc siRNA (Dharmacon SMARTpool ON-
TARGETplus; GE Healthcare Life Sciences, Little Chal-
font, UK) or non-targeting siRNA, (Dharmacon ON-
TARGETplus Nontargeting Pool) in either six well plates
(for RNA and protein expression; 3 × 105 cells per well), or
96 well plates (for drug sensitivity assays; 5000 cells per
well), at a ﬁnal concentration of 25 nM. ABCB1 knock-
down in MCF7-942R cells was carried out in the same way
but with ABCB1-speciﬁc siRNA (Dharmacon SMARTpool
ON-TARGETplus) or non-targeting siRNA (Dharmacon
ON-TARGETplus Nontargeting Pool). RNA preparation,
qRT-PCR, protein preparation, immunoblotting and drug
sensitivity assays were then carried out as described above.
Primers used in sequencing and qRT-PCR are listed in
Supplementary Table S1.
Statistical analyses
Statistical analyses were carried out in Graphpad prism
v7.0. Pairwise comparisons were performed using the Stu-
dent t-test. The Pearson correlation coefﬁcient was used for
gene expression analyses. To assess whether ABC-transport
inhibitors signiﬁcantly alter the GI50 of CDK7i, in CDK7
inhibitor-resistant cell lines, the extra sum-of-squares F test
was used.
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